{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:06:53Z","timestamp":1773799613382,"version":"3.50.1"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/jcp.0b013e31825cccad","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T19:39:58Z","timestamp":1340221198000},"page":"449-457","source":"Crossref","is-referenced-by-count":28,"title":["Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia"],"prefix":"10.1097","volume":"32","author":[{"given":"Andreas","family":"Schreiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Niehaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser Aldien","family":"Shuriquie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaire","family":"Aadamsoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Korcsog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pitsa","family":"Theodoropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena Garc\u00eda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alp","family":"\u00dc\u00e7ok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bergmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Hoeben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":". Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":". A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","article-title":". World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.","volume":"100","author":"Tandon","year":"2008","journal-title":"Schizophr Res"},{"key":"R4-3-20210128","first-page":"1041","article-title":"Experimental antipsychotics and metabolic adverse effectsfindings from clinical trials.","volume":"10","author":"Tschoner","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"issue":"suppl 3","key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.euroneuro.2006.06.003","article-title":"Differential metabolic effects of antipsychotic treatments.","volume":"16","author":"Haupt","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"suppl 4","key":"R6-3-20210128","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk.","volume":"68","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/070674370905400408","article-title":". An epidemiological study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.","volume":"54","author":"Kisely","year":"2009","journal-title":"Can J Psychiatry"},{"issue":"suppl 3","key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.7075su1c.05","article-title":"Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.","volume":"70","author":"Newcomer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4088\/JCP.08m04132","article-title":". A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.","volume":"70","author":"Newcomer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":". Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","article-title":". Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.","volume":"70","author":"Smith","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4088\/JCP.08m04267","article-title":". The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.","volume":"70","author":"Meyer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","article-title":"Fedder DO, talien GJ, et al.. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.","volume":"59","author":"Koro","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","article-title":". A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.","volume":"65","author":"Fleischhacker","year":"2009","journal-title":"Biol Psychiatry"},{"key":"R16-3-20210128","first-page":"22","article-title":". Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.","volume":"43","author":"Cerit","year":"2010","journal-title":"Psychopharmacol Bull"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2008.01.004","article-title":". Metabolic syndrome in first episode schizophreniaa randomized double-blind controlled, short-term prospective study.","volume":"101","author":"Saddichha","year":"2008","journal-title":"Schizophr Res"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","article-title":". Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.","volume":"101","author":"De Hert","year":"2008","journal-title":"Schizophr Res"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.amepre.2008.11.020","article-title":". Obesity among those with mental disorders. A National Institute of Mental Health meeting report.","volume":"36","author":"Allison","year":"2009","journal-title":"Am J Prev Med"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1176\/ps.2009.60.8.1059","article-title":". Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey.","volume":"60","author":"Weber","year":"2009","journal-title":"Psychiatr Serv"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jpsychires.2009.03.002","article-title":". The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year.","volume":"43","author":"Schorr","year":"2009","journal-title":"J Psychiatr Res"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":". Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1185\/030079906X132613","article-title":"Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.","volume":"22","author":"Conley","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":". Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":". Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":". Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":". Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.","volume":"27","author":"Kramer","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":". Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.","volume":"69","author":"Meltzer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":". A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-244X-11-21","article-title":". Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.","volume":"11","author":"Turkoz","year":"2011","journal-title":"BMC Psychiatry"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/YIC.0b013e328314e1f3","article-title":". Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.","volume":"23","author":"Emsley","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/qjmed\/hcm044","article-title":"Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review.","volume":"100","author":"Leslie","year":"2007","journal-title":"QJM Int J Med"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","article-title":". A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.","volume":"68","author":"Perez-Iglesias","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R34-3-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":". Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr Res"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JCP.0b013e31820fcea3","article-title":". Metabolic effects of olanzapine in patients with newly diagnosed psychosis.","volume":"31","author":"Fernandez-Egea","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","article-title":". Use of metabolic markers to identify overweight individuals who are insulin resistant.","volume":"139","author":"McLaughlin","year":"2003","journal-title":"Ann Intern Med"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1210\/jc.2004-2460","article-title":". Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model assessed beta-cell function in patients with type 2 diabetes.","volume":"90","author":"Mari","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":". Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.","volume":"160","author":"Kane","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"suppl 8","key":"R39-3-20210128","first-page":"S3","article-title":"Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.","volume":"14","author":"Cziraky","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2009.07.057","article-title":"Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterolhigh-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.","volume":"55","author":"Arsenault","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R41-3-20210128","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2008.11.014","article-title":". The triglyceridehigh-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Womens Ischemia Syndrome Evaluation (WISE).","volume":"157","author":"Bittner","year":"2009","journal-title":"Am Heart J"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.numecd.2008.09.003","article-title":". TriglycerideHDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men.","volume":"19","author":"Hadaegh","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R43-3-20210128","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1559-4572.2008.00044.x","article-title":"The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus.","volume":"4","author":"Ginsberg","year":"2009","journal-title":"J Cardiometab Syndr"},{"key":"R44-3-20210128","first-page":"69","article-title":"Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics.","volume":"22","author":"Kozumplik","year":"2010","journal-title":"Psychiatr Danub"},{"key":"R45-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.genhosppsych.2008.09.012","article-title":". The impact of obesity on health care costs among persons with schizophrenia.","volume":"31","author":"Chwastiak","year":"2009","journal-title":"Gen Hosp Psychiatry"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0091270010368678","article-title":"Effect of antipsychotic medications on glucose and lipid levels.","volume":"51","author":"Chaggar","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R47-3-20210128","first-page":"CD006654","article-title":". Olanzapine versus other atypical antipsychotics for schizophrenia.","volume":"3","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R48-3-20210128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4088\/JCP.v69n0214","article-title":". A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.","volume":"69","author":"Meltzer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R49-3-20210128","first-page":"649","article-title":"The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.","volume":"23","author":"Naber","year":"2009","journal-title":"CNS Drugs"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/JCP.0b013e3181faf670","article-title":". Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder: post hoc analyses of 3 randomized, controlled clinical trials.","volume":"30","author":"Hoffmann","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R51-3-20210128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.euroneuro.2006.11.007","article-title":". A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.","volume":"17","author":"Arango","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"R53-3-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","article-title":". Olanzapine: an updated review of its use in the management of schizophrenia.","volume":"61","author":"Bhana","year":"2001","journal-title":"Drugs"},{"issue":"suppl 10","key":"R54-3-20210128","first-page":"31","article-title":"Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.","volume":"60","author":"Stahl","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R55-3-20210128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10673220216279","article-title":"Optimal dosing atypical antipsychotics in adults: a review of the current evidence.","volume":"10","author":"Citrome","year":"2002","journal-title":"Harv Rev Psychiatry"},{"key":"R56-3-20210128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/NDT.S1365","article-title":"Paliperidone ER: a review of the clinical trial data.","volume":"3","author":"Janicak","year":"2007","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201208000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:17:49Z","timestamp":1618035469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201208000-00003"}},"subtitle":["A Prospective, Randomized, Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31825cccad","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}